Direct-acting antiviral agents resistance-associated polymorphisms in Chinese treatment-naive patients infected with genotype 1b hepatitis C virus

Chinese Medical Journal

Volumn 128, Issue 19, 2015, Pages 2625-2631

  Wang, Ye ^a   Rao, Hui Ying ^a   Xie, Xing Wang ^a   Wei, Lai ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Antiviral resistance; Direct antiviral agents; Hepatitis C virus

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; HEMOGLOBIN; LEDIPASVIR; SIMEPREVIR; SOFOSBUVIR; BENZIMIDAZOLE DERIVATIVE; BMS-790052; FLUORENE DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; AGED; CHINA; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PATHOGENICITY;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CHINA; DRUG RESISTANCE, VIRAL; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SIMEPREVIR;

EID: 84942243558     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.166038     Document Type: Article

References (34)

1. Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 2014;146:1145-50.e1-4.
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15.
3. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013;58:428-38.
4. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010;30:240-50.
5. Pawlotsky JM. New hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92.
6. Thompson AJ, Locarnini SA, Beard MR. Resistance to anti-HCV protease inhibitors. Curr Opin Virol 2011;1:599-606.
7. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 2013;207 Suppl 1:S33-339.
8. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-26.
9. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015;61:56-65.
10. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: A randomised study. Gut 2015;64:948-56.
11. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-13.
12. Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014;61:219-27.
13. Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014;49:941-53.
14. Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, McCormick AL, et al. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure. Antiviral Res 2014;105:112-7.
15. Hoffmann L, Ramos JA, Souza EV, Araüjo Ramos AL, Villela-Nogueira CA, Urmenyi TP, et al. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: A prospective longitudinal study. Virol J 2013;10:57.
16. Liu Y, Cai Q, Li Z, Shao X, Luo Q, Zhang X, et al. Effect of drug-resistance mutations on antiviral agents in HCV patients. Antivir Ther 2014. doi: 10.3851/IMP2852. [Epub ahead of print].
17. Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslen L, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 2013;99:12-7.
18. Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, Yoshimi S, et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat 2015;22:158-65.
19. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): A randomised, open-label phase 2 trial. Lancet 2015;385:1075-86.
20. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013;58:646-54.
21. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 2014;57:2047-57.
22. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014;383:515-23.
23. Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 2013;57:6333-40.
24. Wyles DL, Gutierrez JA. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat 2014;21:229-40.
25. McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, et al. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther 2014;19:479-90.
26. Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother 2014;15:2609-22.
27. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645-53.
28. Marino Z, van Bömmel F, Forns X, Berg T. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut 2014;63:207-15.
29. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148:108-17.
30. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
31. Alves R, Queiroz AT, Pessoa MG, da Silva EF, Mazo DF, Carrilho FJ, et al. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank. J Viral Hepat 2013;20:414-21.
32. Jaspe RC, Sulbarân YF, Sulbarân MZ, Loureiro CL, Rangel HR,Pujol FH. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates. Virol J 2012;9:214.
33. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014;146:736-743.e1.
34. Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB, et al. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 2015;477:1-9.